Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 286

1.

[Antidepressant effect of ketamine, a N-methyl-D-aspartate (NMDA) glutamate receptor antagonist, in the therapy of treatment-resistant depression].

Gosek P, Chojnacka M, Bieńkowski P, Swiecicki Ł.

Psychiatr Pol. 2012 Mar-Apr;46(2):283-94. Review. Polish.

PMID:
23214398
2.

Intravenous ketamine for treatment-resistant major depressive disorder.

Covvey JR, Crawford AN, Lowe DK.

Ann Pharmacother. 2012 Jan;46(1):117-23. doi: 10.1345/aph.1Q371. Epub 2011 Dec 20. Review.

PMID:
22190250
3.

A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.

Naughton M, Clarke G, O'Leary OF, Cryan JF, Dinan TG.

J Affect Disord. 2014 Mar;156:24-35. doi: 10.1016/j.jad.2013.11.014. Epub 2013 Dec 10. Review.

PMID:
24388038
4.

An extension of hypotheses regarding rapid-acting, treatment-refractory, and conventional antidepressant activity of dextromethorphan and dextrorphan.

Lauterbach EC.

Med Hypotheses. 2012 Jun;78(6):693-702. doi: 10.1016/j.mehy.2012.02.012. Epub 2012 Mar 7.

PMID:
22401777
5.

Ketamine as a novel antidepressant: from synapse to behavior.

Murrough JW.

Clin Pharmacol Ther. 2012 Feb;91(2):303-9. doi: 10.1038/clpt.2011.244. Epub 2011 Dec 28. Review.

6.

NMDA antagonists under investigation for the treatment of major depressive disorder.

Pochwat B, Pałucha-Poniewiera A, Szewczyk B, Pilc A, Nowak G.

Expert Opin Investig Drugs. 2014 Sep;23(9):1181-92. doi: 10.1517/13543784.2014.918951. Epub 2014 May 12. Review. Erratum in: Expert Opin Investig Drugs. 2014 Oct;23(10):1457.

PMID:
24818801
7.

[Ketamine for treatment of acute depression].

Hjerrild S, Bjerre J, Pedersen RH, Videbech P.

Ugeskr Laeger. 2013 Sep 9;175(37):2090-3. Review. Danish.

PMID:
24011203
8.

NMDA antagonist treatment of depression.

Williams NR, Schatzberg AF.

Curr Opin Neurobiol. 2016 Feb;36:112-7. doi: 10.1016/j.conb.2015.11.001. Epub 2015 Dec 11. Review.

PMID:
26687375
9.

Ketamine as an alternative treatment for treatment-resistant depression.

Dowben JS, Grant JS, Keltner NL.

Perspect Psychiatr Care. 2013 Jan;49(1):2-4. doi: 10.1111/ppc.12006. Epub 2012 Dec 30. Review. No abstract available.

PMID:
23293991
10.

Targeting of NMDA receptors in the treatment of major depression.

Dang YH, Ma XC, Zhang JC, Ren Q, Wu J, Gao CG, Hashimoto K.

Curr Pharm Des. 2014;20(32):5151-9. Review.

PMID:
24410564
11.

Exploiting N-methyl-d-aspartate channel blockade for a rapid antidepressant response in major depressive disorder.

Blier P.

Biol Psychiatry. 2013 Aug 15;74(4):238-9. doi: 10.1016/j.biopsych.2013.05.029. No abstract available.

PMID:
23885752
12.

Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.

Murrough JW, Iosifescu DV, Chang LC, Al Jurdi RK, Green CE, Perez AM, Iqbal S, Pillemer S, Foulkes A, Shah A, Charney DS, Mathew SJ.

Am J Psychiatry. 2013 Oct;170(10):1134-42. doi: 10.1176/appi.ajp.2013.13030392.

13.

[Effectiveness of ketamine in depressed patients resistant to ECT or rTMS therapy].

Gosek P, Chojnacka M, Bieńkowski P, Swiecicki Ł.

Psychiatr Pol. 2014 Jan-Feb;48(1):49-58. Polish.

PMID:
24946434
14.

A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.

Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK.

Arch Gen Psychiatry. 2006 Aug;63(8):856-64.

PMID:
16894061
15.

The promise of ketamine for treatment-resistant depression: current evidence and future directions.

DeWilde KE, Levitch CF, Murrough JW, Mathew SJ, Iosifescu DV.

Ann N Y Acad Sci. 2015 May;1345:47-58. doi: 10.1111/nyas.12646. Epub 2015 Feb 3. Review.

16.

Ketamine for treatment-resistant unipolar depression: current evidence.

Mathew SJ, Shah A, Lapidus K, Clark C, Jarun N, Ostermeyer B, Murrough JW.

CNS Drugs. 2012 Mar 1;26(3):189-204. doi: 10.2165/11599770-000000000-00000. Review.

17.

[Ketamine--a new treatment option for therapy-resistant depression].

Köhler S, Betzler F.

Fortschr Neurol Psychiatr. 2015 Feb;83(2):91-7. doi: 10.1055/s-0034-1398967. Epub 2015 Feb 27. Review. German.

PMID:
25723773
18.

Ketamine for the treatment of depression.

Howland RH.

J Psychosoc Nurs Ment Health Serv. 2013 Jan;51(1):11-4.

PMID:
23413455
19.

Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist.

Machado-Vieira R, Yuan P, Brutsche N, DiazGranados N, Luckenbaugh D, Manji HK, Zarate CA Jr.

J Clin Psychiatry. 2009 Dec;70(12):1662-6. doi: 10.4088/JCP.08m04659. Epub 2009 Sep 8.

20.

Ketamine and the potential role for rapid-acting antidepressant medications.

Krystal JH.

Swiss Med Wkly. 2007 Apr 21;137(15-16):215-6. No abstract available.

PMID:
17525875

Supplemental Content

Support Center